Head to Head Survey: BioNxt Solutions (OTCMKTS:BNXTF) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL)

BioNxt Solutions (OTCMKTS:BNXTF) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Risk and Volatility

BioNxt Solutions has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500.

Institutional & Insider Ownership

98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares BioNxt Solutions and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioNxt Solutions	-19,165.00%	N/A	-663.55%
Madrigal Pharmaceuticals	-54.68%	-38.38%	-27.32%

Valuation and Earnings

This table compares BioNxt Solutions and Madrigal Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNxt Solutions	$20,000.00	4,341.00	-$3.88 million	($0.04)	-18.75
Madrigal Pharmaceuticals	$180.13 million	50.81	-$465.89 million	($12.85)	-32.08

BioNxt Solutions has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNxt Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for BioNxt Solutions and Madrigal Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNxt Solutions	0	0	0	0	0.00
Madrigal Pharmaceuticals	0	1	7	0	2.88

Madrigal Pharmaceuticals has a consensus target price of $445.7143, suggesting a potential upside of 8.12%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than BioNxt Solutions.

Summary

Madrigal Pharmaceuticals beats BioNxt Solutions on 8 of the 14 factors compared between the two stocks.

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.